ASCO 2019 | Palbociclib & fulvestrant for breast cancer

Ramon De Mello, MD, PhD, FACP, of the University of Algarve, Faro, Portugal, gives an updates on the PALOMA-3 study, a Phase III clinical trial with the primary objective of demonstrating the superiority of palbociclib in combination with fulvestrant over fulvestrant alone in prolonging PFS in women with HR+, HER2 negative metastatic breast cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.